Company intelligence / Profile preview

Taibang Biologic Group

Beijing, China

Ownership: Private
Employees: ~2246
Development stage: Commercial

Overview

The company is a leading biopharmaceutical company in China that produces plasma-derived products. It was previously listed on Nasdaq but was taken private in April 2021 in a $4.6-4.8 billion deal by investors including Centurium Capital, CITIC Capital, and Hillhouse Capital[2][6][8].

Therapeutic areas: OtherImmunologyRare Diseases
Modalities: Plasma-derived products
Industry: Biotech

Drug pipeline

6 assets

Human Albumin

Commercial

Indications: Blood volume deficiency

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Taibang Biologic Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taibang Biologic Group.

Explore the full profile